To identify circulating mediators that are released after surgery and which are responsible for macrophage activation.
ID
Source
Brief title
Condition
- Malignant and unspecified neoplasms gastrointestinal NEC
- Gastrointestinal neoplasms malignant and unspecified
- Gastrointestinal therapeutic procedures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Capacity of pre- per- and post operative plasma to activate macrophages in
vitro. Endpoints are production of reactive oxygen species (ROS) and conversion
of MTT to formazan (this allows to assess the viability of cells).
- Identification of the inflammatory factors released after surgery that are
responsible for macrophage activation. Endpoints are decrease of ROS production
and conversion of MTT in the presence of blocking agents against inflammatory
mediators.
Secondary outcome
not applicable
Background summary
Metastases in CRC patients originate from tumor cells that have disseminated
from the primary tumor, and either spread via the venous circulation, the
lymphatics or directly into the peritoneal cavity. Under physiological
circumstances, the process of metastases formation is highly inefficient, as
disseminated tumor cells have a limited life span and are rapidly eliminated by
the immune system. However, evidence that inflammatory responses as a result of
surgical trauma enhance the risk of metastases development is accumulating. We
previously demonstrated that post-operative plasma of rats, receiving
peritoneal surgery enhances activation of macrophages. Because we additionally
demonstrated that macrophage activation leads to endothelial damage and
enhanced tumor cell adhesion in the liver, we hypothesize that surgery creates
permissive circumstances for tumor cells to adhere in target organs and thereby
increase chances of metastatic development.
Study objective
To identify circulating mediators that are released after surgery and which are
responsible for macrophage activation.
Study design
Prospective, observational pilot study.
Study burden and risks
The burden associated with participation consists of extra blood sampling (in
total 24 ml) taken pre-, per- and postoperatively. Therapy will neither be
delayed nor altered and no extra complications are expected.
Patients participating in this study will not directly benefit. However,
obtained results may lead to novel per-operative therapeutic adjuvant
strategies, which will help future patients.
Van der Boechorststraat 7
Amsterdam 1081BT
NL
Van der Boechorststraat 7
Amsterdam 1081BT
NL
Listed location countries
Age
Inclusion criteria
Resection of primary colorectal carcinoma.
Exclusion criteria
Excisting infection: Crohn's disease or ulcerative colitis
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL36125.029.11 |